From Patient to Pioneer: Sharron S. Rouse on Advocacy, APOL1 Awareness, and Community Impact

For Sharron S. Rouse, advocacy was never part of the original plan. With a career rooted in education, curriculum development, and leadership, she spent years helping others learn, grow, and succeed. But after being diagnosed with Focal Segmental Glomerulosclerosis (FSGS), receiving a life-saving kidney transplant from her sister, and later discovering her disease was linked to APOL1 genetic risk variants, her life's work took on a new purpose.

Today, as founder and executive director of Kindness for Kidneys International and co-founder of the APOL1 Action Alliance, Rouse has become a respected voice in kidney disease advocacy, patient education, and community engagement. Her mission remains simple: ensure that patients and families have access to the information, support, and opportunities they need to make informed decisions about their health.

In this Rare360 discussion, Rouse shares insights on advocacy, genetics, trust in healthcare, and the future of APOL1 awareness.

1. Your career began in education and leadership. Do you see parallels between those roles and the advocate you've become today?
   

   Absolutely. At their core, both roles are about helping people navigate complex information and empowering them to make informed decisions. Whether I was developing curriculum or supporting kidney patients, the goal has always been the same: meet people where they are, listen to their needs, and provide tools that help them move forward with confidence.

   Advocacy is education. The difference is that now the lessons are often deeply personal, and the stakes can be life-changing.
   

2. Receiving a kidney from your sister changed your life. How has that experience shaped the way you think about family and responsibility?

   My transplant was a gift that extended far beyond me. It reminded me that kidney disease affects entire families, not just individual patients. My sister's willingness to donate gave me a second chance at life, but it also reinforced my responsibility to honor that gift by serving others.

   Every day, I think about the families sitting in clinic waiting rooms, navigating uncertainty together. That's who I advocate for.
   

3. Learning your kidney disease was connected to APOL1 risk variants added a genetic dimension to your journey. What questions did that discovery answer?
   

   It answered one of the most important questions many patients ask: "Why did this happen to me?"

   For years, many families have lived with kidney disease without understanding the underlying cause. Learning about APOL1 helped provide context for my experience, but it also raised new questions about awareness, access to testing, and how we ensure communities have accurate information about genetic risk.

   Knowledge is powerful, but only when it's accessible.
   

4. APOL1-related kidney disease disproportionately affects people of African ancestry. How do we discuss genetics without creating stigma?
   

   We start by leading with education, not fear.

   Genetics should never be used to define people or limit opportunities. Instead, genetic information should be viewed as one piece of the overall health picture. Our conversations must emphasize empowerment, informed decision-making, and equitable access to care.

   The goal is not to label communities. The goal is to ensure communities have the information they deserve.
   

5. What is the biggest misconception people have about APOL1 today?

   One of the most common misconceptions is that having APOL1 risk variants means someone is destined to develop kidney disease.

   That simply isn't true.

   Many people with APOL1 risk variants never develop kidney disease. Genetics may increase risk, but risk is not destiny. That's why education is so important. People need accurate information that helps them understand both the risks and the realities.
   

6. At what point did you realize your voice carried influence beyond your own story?

   I think it happened when patients started telling me that my story helped them feel less alone.

   Initially, I shared my experience because I wanted others to know they weren't the only ones facing these challenges. Over time, I realized that storytelling creates connection, and connection creates community.

   The moment you recognize your story can help someone else navigate theirs, advocacy becomes bigger than you.
   

7. What have patients taught you about trust in healthcare?

   Patients have taught me that trust cannot be assumed, it must be earned.

   Communities want transparency. They want to know that their experiences matter and that their concerns are being heard. When patients feel respected and included in decisions, trust grows. When they feel overlooked, trust erodes quickly.

   Healthcare systems often focus on delivering information. Patients are asking for relationships.
   

8. What does meaningful community partnership look like?

   Meaningful partnership means involving communities before decisions are made, not after.

   Too often, organizations seek community input once plans are already finalized. True partnership means inviting patients and caregivers to help shape priorities, programs, and research from the beginning.

   Patients are not simply stakeholders. They are experts in their own lived experiences.
   

9. Through your work in research and community engagement, what distinguishes research programs that genuinely engage communities?
   

   The best programs understand that engagement is not an event; it's a relationship.

   They invest time in listening. They communicate clearly. They share results with participants. Most importantly, they demonstrate that community voices influence decisions.

   People want to know that their participation matters. Genuine engagement makes that clear.
   

10. Looking ahead, what gives you the most hope about the future of APOL1 awareness and kidney care?
    

    What gives me hope is that we are finally seeing greater collaboration between patients, researchers, clinicians, and advocacy organizations.

    We're having conversations today that weren't happening a decade ago. Awareness is growing. Research is advancing. New therapies are being explored. Most importantly, patients are increasingly being recognized as essential partners in shaping the future of care.

    That progress matters.
    

11. If you could change one thing about the kidney disease journey for newly diagnosed patients tomorrow, what would it be?
    

    I would ensure that no patient has to navigate their diagnosis alone.

    Every patient deserves access to understandable information, supportive resources, knowledgeable healthcare professionals, and a community that understands what they're experiencing.

    A diagnosis can feel overwhelming, but it shouldn't feel isolating. My goal has always been to help patients and families know that support exists, hope exists, and they do not have to walk this journey by themselves.
    

Closing Remarks

For Sharron S. Rouse, advocacy is about far more than raising awareness. It's about creating pathways to understanding, support, and opportunities for patients and families navigating kidney disease.

Drawing from her experiences as an educator, transplant recipient, and community leader, she continues to champion a future where patients are informed, empowered, and meaningfully included in conversations about research, care, and health equity. Through her work with Kindness for Kidneys International, the APOL1 Action Alliance, and numerous research and advocacy initiatives, Rouse remains committed to ensuring that no patient feels alone on their journey.

As awareness of APOL1-mediated kidney disease continues to grow and new advances emerge in research and treatment, she believes the most important progress will come from listening to the voices of those most affected.

"Every patient deserves access to knowledge, support, and hope," Rouse says. "When we bring patients, families, healthcare providers, researchers, and advocates together, we create opportunities to improve outcomes and change lives. That's the future I'm working toward."

To learn more about Sharron S. Rouse and her advocacy efforts, visit Kindness for Kidneys International and APOL1 Action Alliance and follow the growing movement to advance education, awareness, and equity in kidney health.